Robitussin for Cough
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate how well Robitussin cough syrups improve the quality of life for individuals with coughs from the common cold. Participants will use either a daytime syrup or a combination of daytime and nighttime syrups. The trial seeks individuals who have experienced a cough from a cold starting within the last 48 hours, with symptoms severe enough to disrupt sleep over the past two nights. Those who have not recently used any cough products and are in good health may be suitable for this study. As a Phase 4 trial, this research helps to understand how the already FDA-approved and effective treatment benefits a broader range of patients.
Do I have to stop taking my current medications to join the trial?
Yes, you may need to stop taking certain medications, especially if they interact with the study products or contain specific ingredients like dextromethorphan, guaifenesin, or doxylamine. If you're taking medications for mental health, heart problems, or using sedatives, you might not be eligible to participate.
What is the safety track record for these treatments?
Previous studies have shown that Robitussin Maximum Strength Cough and Chest Congestion DM syrup is widely used and generally well-tolerated. The FDA has not raised safety concerns about its use. This syrup relieves cough and chest congestion, common cold symptoms.
The nighttime version, Robitussin Maximum Strength Nighttime Cough DM, controls cough and aids sleep. Like the daytime version, it is considered safe.
Both syrups include instructions to avoid exceeding the recommended doses in a 24-hour period to prevent side effects. As with many over-the-counter medicines, following the dosing guidelines carefully is important for safety. Overall, both daytime and nighttime Robitussin products are designed to be safe when used as directed.12345Why are researchers enthusiastic about this study treatment?
Researchers are excited about using Robitussin for cough relief because it offers a comprehensive approach to managing symptoms both during the day and at night. Unlike standard treatments that often focus solely on daytime relief, one arm of the trial combines Robitussin Maximum Strength Cough and Chest Congestion DM syrup with a nighttime formula, potentially providing round-the-clock symptom control. This dual approach could mean fewer disruptions to sleep due to coughing, which is a significant advantage over typical daytime-only options. Additionally, the maximum strength formulation aims to tackle both cough and chest congestion, addressing multiple symptoms simultaneously.
What is the effectiveness track record for Robitussin in treating cough associated with the common cold?
Research has shown that Robitussin Maximum Strength Cough and Chest Congestion DM effectively relieves coughs caused by minor throat and chest irritation, such as those from a common cold. In this trial, participants in one arm will receive the daytime syrup, which controls coughs and loosens mucus, easing breathing. Studies indicate that this formula provides quick and effective relief from coughing.
Participants in another arm will receive both the daytime and nighttime syrups. The nighttime syrup is similar but also includes ingredients to aid sleep, which can help manage symptoms at night. While the nighttime formula may cause drowsiness, it effectively reduces cough and chest congestion, promoting better sleep. Overall, Robitussin is well-known for relieving coughs and improving comfort during a cold.16789Are You a Good Fit for This Trial?
This trial is for adults over 18 in the US who started having a cough from a cold within the last 48 hours, with at least moderate severity and one other cold symptom. They must be in good health overall, have had sleep affected by the cold, agree to electronic consent, follow product labels, self-treat using study treatments, own a mobile device with internet for surveys and not have used certain cough medications recently.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Robitussin Maximum Strength Cough and Chest Congestion DM syrup for up to 8 days or until resolution of symptoms
Follow-up
Participants are monitored for changes in quality of life and symptom scores using WURSS-21 and other QoL assessments
What Are the Treatments Tested in This Trial?
Interventions
- Robitussin
Find a Clinic Near You
Who Is Running the Clinical Trial?
HALEON
Lead Sponsor